How to replace the lost keys? Strategies toward safer KV7 channel openers.
暂无分享,去创建一个
[1] Sun Choi,et al. Promiscuous gating modifiers target the voltage sensor of Kv7.2, TRPV1, and Hv1 cation channels , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] Ghanshyam Yadav,et al. Role of flupirtine in reducing preoperative anxiety of patients undergoing craniotomy procedure , 2017, Saudi journal of anaesthesia.
[3] B. Terhaag,et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial* , 2008, Current medical research and opinion.
[4] Maurizio Taglialatela,et al. Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites. , 2017, Current medicinal chemistry.
[5] C. Bundgaard,et al. Antipsychotic-Like Effect of Retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic Acid Ester], a KCNQ Potassium Channel Opener, via Modulation of Mesolimbic Dopaminergic Neurotransmission , 2009, Journal of Pharmacology and Experimental Therapeutics.
[6] R. Bergman,et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. , 2014, JAMA dermatology.
[7] C. Elger,et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy , 2010, Neurology.
[8] H. Husum,et al. Effect of the new antiepileptic drug retigabine in a rodent model of mania , 2008, Epilepsy & Behavior.
[9] Jose A. Lopez-Garcia,et al. Effects of novel subtype selective M-current activators on spinal reflexes in vitro: Comparison with retigabine , 2016, Neuropharmacology.
[10] Julian Solway,et al. Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy. , 2012, American journal of physiology. Lung cellular and molecular physiology.
[11] R. Leroy,et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy , 2011, Neurology.
[12] Angel Lanas,et al. We Are Using Too Many PPIs, and We Need to Stop: A European Perspective , 2016, The American Journal of Gastroenterology.
[13] Robert H. Brown,et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. , 2014, Cell reports.
[14] Thomas Berg,et al. N‐acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[15] B S Brown,et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. , 1998, Science.
[16] James O McNamara,et al. In Vivo Profile of ICA-27243 [N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a Potent and Selective KCNQ2/Q3 (Kv7.2/Kv7.3) Activator in Rodent Anticonvulsant Models , 2008, Journal of Pharmacology and Experimental Therapeutics.
[17] Mario Giorgi,et al. Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test. , 2015, European journal of pharmacology.
[18] Edeltraut Garbe,et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. , 2015, British journal of clinical pharmacology.
[19] Zhen Liu,et al. KCNQ2/3/5 channels in dorsal root ganglion neurons can be therapeutic targets of neuropathic pain in diabetic rats , 2018, Molecular pain.
[20] Anastasios V Tzingounis,et al. Potent KCNQ2/3-Specific Channel Activator Suppresses In Vivo Epileptic Activity and Prevents the Development of Tinnitus , 2015, The Journal of Neuroscience.
[21] C. Grunwald,et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[22] Paul C Trippier,et al. Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2). , 2017, Journal of medicinal chemistry.
[23] Robert W. Williams,et al. Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking. , 2017, Alcohol.
[24] Bernd Terhaag,et al. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study , 2012, Current medical research and opinion.
[25] Stephanie D Nichols,et al. A New Tool to Tackle the Opioid Epidemic: Description, Utility, and Results from the Maine Diversion Alert Program , 2017, Pharmacotherapy.
[26] Andreas Link,et al. Oxidation Potentials of N‐Modified Derivatives of the Analgesic Flupirtine Linked to Potassium KV7 Channel Opening Activity But Not Hepatocyte Toxicity , 2015, ChemMedChem.
[27] Takashi Okada,et al. MicroRNA cluster miR-17-92 regulates multiple functionally related voltage-gated potassium channels in chronic neuropathic pain , 2017, Nature Communications.
[28] Michal Douša,et al. Identification, characterization, synthesis and HPLC quantification of new process-related impurities and degradation products in retigabine. , 2014, Journal of pharmaceutical and biomedical analysis.
[29] John Malysz,et al. Molecular Expression and Pharmacological Evidence for a Functional Role of Kv7 Channel Subtypes in Guinea Pig Urinary Bladder Smooth Muscle , 2013, PloS one.
[30] Karen Methling,et al. Quantitative LC-MS/MS determination of flupirtine, its N-acetylated and two mercapturic acid derivatives in man. , 2015, Journal of pharmaceutical and biomedical analysis.
[31] D. Strøbæk,et al. Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels , 2005, Journal of Pharmacology and Experimental Therapeutics.
[32] Shinichi Hirose,et al. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations , 2016, PloS one.
[33] Jaideep Kapur,et al. Flupirtine and diazepam combination terminates established status epilepticus: results in three rodent models , 2017, Annals of clinical and translational neurology.
[34] Qi Gao,et al. Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides. , 2004, Bioorganic & medicinal chemistry letters.
[35] Stefan Boehm,et al. δ Subunit‐containing GABAA receptors are preferred targets for the centrally acting analgesic flupirtine , 2015, British journal of pharmacology.
[36] Y Shweikh,et al. Activation of KV7 channels stimulates vasodilatation of human placental chorionic plate arteries. , 2015, Placenta.
[37] Eric Marsh,et al. KCNQ2 encephalopathy , 2016, Neurology: Genetics.
[38] L. Rønn,et al. Kv 7 positive modulators reduce detrusor overactivity and increase bladder capacity in rats. , 2012, Basic & clinical pharmacology & toxicology.
[39] Guang-Di Chen,et al. Potassium ion channel openers, Maxipost and Retigabine, protect against peripheral salicylate ototoxicity in rats , 2015, Hearing Research.
[40] Yasunori Sato,et al. Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: An immunohistochemical study , 2011, Experimental Neurology.
[41] Palle Christophersen,et al. Characterization of a novel high-potency positive modulator of K(v)7 channels. , 2013, European journal of pharmacology.
[42] Stefan Boehm,et al. Concomitant facilitation of GABAA receptors and KV7 channels by the non‐opioid analgesic flupirtine , 2012, British journal of pharmacology.
[43] Haixia Gao,et al. Intracellular zinc activates KCNQ channels by reducing their dependence on phosphatidylinositol 4,5-bisphosphate , 2017, Proceedings of the National Academy of Sciences.
[44] Yuji Ikegaya,et al. Heterogeneous effects of antiepileptic drugs in an in vitro epilepsy model – a functional multineuron calcium imaging study , 2015, The European journal of neuroscience.
[45] Andreas Link,et al. Synthesis and potassium KV7 channel opening activity of thioether analogues of the analgesic flupirtine. , 2018, Organic & biomolecular chemistry.
[46] Geoffrey W. Abbott,et al. Direct neurotransmitter activation of voltage-gated potassium channels , 2018, Nature Communications.
[47] Juan Ren,et al. Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain. , 2015, Oncology reports.
[48] Ming Zhou,et al. Centipedes subdue giant prey by blocking KCNQ channels , 2018, Proceedings of the National Academy of Sciences.
[49] C. Petit,et al. KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[50] Vincent Seutin,et al. Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS , 2008, The Journal of physiology.
[51] Scott M. Rawls,et al. KCNQ2/3 channel agonist flupirtine reduces cocaine place preference in rats , 2017, Behavioural pharmacology.
[52] Holger Lerche,et al. KV7 channelopathies , 2010, Pflügers Archiv - European Journal of Physiology.
[53] Piotr Radziszewski,et al. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. , 2012, British journal of clinical pharmacology.
[54] A. Wickenden,et al. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site , 2009, Neuroscience Letters.
[55] G. Landes,et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias , 1996, Nature Genetics.
[56] S. H. Hussaini,et al. Idiosyncratic drug-induced liver injury: an overview , 2007, Expert opinion on drug safety.
[57] Qing Yang,et al. Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury. , 2017, Journal of neurotrauma.
[58] Kenneth L Byron,et al. Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels. , 2016, Pharmacology & therapeutics.
[59] Thanos Tzounopoulos,et al. Noise-induced plasticity of KCNQ2/3 and HCN channels underlies vulnerability and resilience to tinnitus , 2015, eLife.
[60] Elissa J Chesler,et al. Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption , 2016, Addiction biology.
[61] Fan Zhang,et al. Activation of KCNQ2/3 Potassium Channels by Novel Pyrazolo[1,5-a]pyrimidin-7(4H)-One Derivatives , 2011, Pharmacology.
[62] Lal D. Mishra,et al. Evaluating the Role of Flupirtine for Postcraniotomy Pain and Compare it With Diclofenac Sodium: A Prospective, Randomized, Double Blind, Placebo-controlled Study , 2014, Journal of neurosurgical anesthesiology.
[63] Meng Cui,et al. Ca2+-Calmodulin and PIP2 interactions at the proximal C-terminus of Kv7 channels , 2017, Channels.
[64] Mathias Bähr,et al. The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis , 2015, Oncotarget.
[65] T. Tzounopoulos,et al. Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of tinnitus , 2013, Proceedings of the National Academy of Sciences.
[66] D. A. Brown,et al. Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine , 2001, The Journal of Neuroscience.
[67] B. Attali,et al. Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties , 2005, Molecular Pharmacology.
[68] P. Delmas,et al. Pathways modulating neural KCNQ/M (Kv7) potassium channels , 2005, Nature Reviews Neuroscience.
[69] Nicole Schmitt,et al. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels , 2006, Neuropharmacology.
[70] Thomas Friedrich,et al. Refinement of the Binding Site and Mode of Action of the Anticonvulsant Retigabine on KCNQ K+ Channels , 2009, Molecular Pharmacology.
[71] Dean P. Jones,et al. Extracellular redox state: refining the definition of oxidative stress in aging. , 2006, Rejuvenation research.
[72] Martin J. Brodie,et al. A case report: retigabine induced oral mucosal dyspigmentation of the hard palate , 2015, BMC oral health.
[73] Ming-Hu Han,et al. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism , 2016, Nature Communications.
[74] M. Nelson,et al. HLA-DRB1*16: 01-DQB1*05 02 is a novel genetic risk factor for flupirtine-induced liver injury , 2016, Pharmacogenetics and genomics.
[75] Jürgen Borlak,et al. Pathology of flupirtine-induced liver injury: , 2011, Virchows Archiv.
[76] Sarah L. Clark,et al. New antiepileptic medication linked to blue discoloration of the skin and eyes , 2015, Therapeutic advances in drug safety.
[77] J Robbins,et al. KCNQ potassium channels: physiology, pathophysiology, and pharmacology. , 2001, Pharmacology & therapeutics.
[78] D. Oliver,et al. Restoration of ion channel function in deafness‐causing KCNQ4 mutants by synthetic channel openers , 2012, British journal of pharmacology.
[79] Karen Methling,et al. Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. , 2015, British journal of clinical pharmacology.
[80] Majid Sheykhzade,et al. Bladder contractility is modulated by Kv7 channels in pig detrusor. , 2013, European journal of pharmacology.
[81] P H Van de Heyning,et al. The use of flupirtine in treatment of tinnitus , 2006, Acta oto-laryngologica. Supplementum.
[82] Ulises Meza,et al. Regulation of Kv7.2/Kv7.3 channels by cholesterol: Relevance of an optimum plasma membrane cholesterol content. , 2018, Biochimica et biophysica acta. Biomembranes.
[83] Pingkai Ouyang,et al. Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents. , 2018, Bioorganic & medicinal chemistry letters.
[84] András Varró,et al. Slow Delayed Rectifier Potassium Current (IKs) and the Repolarization Reserve , 2007, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[85] Mauricio Montal,et al. The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine* , 2015, The Journal of Biological Chemistry.
[86] I. Szelenyi,et al. Flupirtine, a re-discovered drug, revisited , 2013, Inflammation Research.
[87] R. Wörz,et al. Zur Langzeitbehandlung chronischer Schmerzpatienten mit Flupirtin , 2014, MMW - Fortschritte der Medizin.
[88] C. Mancuso,et al. KV7 channels in the human detrusor: channel modulator effects and gene and protein expression , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.
[89] M. Bal,et al. Homomeric and Heteromeric Assembly of KCNQ (Kv7) K+ Channels Assayed by Total Internal Reflection Fluorescence/Fluorescence Resonance Energy Transfer and Patch Clamp Analysis* , 2008, Journal of Biological Chemistry.
[90] Min Li,et al. Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. , 2007, Nature chemical biology.
[91] R. Kass,et al. KCNE1 and KCNE3 modulate KCNQ1 channels by affecting different gating transitions , 2017, Proceedings of the National Academy of Sciences.
[92] Vincent Seutin,et al. The KCNQ Channel Opener Retigabine Inhibits the Activity of Mesencephalic Dopaminergic Systems of the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.
[93] J. Borlak,et al. Correlation versus Causation? Pharmacovigilance of the Analgesic Flupirtine Exemplifies the Need for Refined Spontaneous ADR Reporting , 2011, PloS one.
[94] Qing Lu,et al. Flupirtine attenuates chronic restraint stress-induced cognitive deficits and hippocampal apoptosis in male mice , 2015, Behavioural Brain Research.
[95] Lei Zhang,et al. Discovery of a novel Kv7 channel opener as a treatment for epilepsy. , 2015, Bioorganic & medicinal chemistry letters.
[96] W. Alves,et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures , 2007, Neurology.
[97] Jai Karan,et al. A PROSPECTIVE RANDOMIZED COMPARATIVE EVALUATION OF FLUPIRTINE AND DICLOFENAC SODIUM IN POST INGUINAL HERNIA SURGERY PAIN , 2016 .
[98] B. Abou-Khalil,et al. Ezogabine skin discoloration is reversible after discontinuation , 2017, Epilepsy & Behavior Case Reports.
[99] Maria Virginia Soldovieri,et al. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. , 2008, Current opinion in pharmacology.
[100] Fan Zhang,et al. Activation of neuronal Kv7/KCNQ/M-channels by the opener QO58-lysine and its anti-nociceptive effects on inflammatory pain in rodents , 2016, Acta Pharmacologica Sinica.
[101] A. Nistri,et al. Functional up‐regulation of the M‐current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons , 2018, The Journal of physiology.
[102] Meng Wu,et al. Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions* , 2010, The Journal of Biological Chemistry.
[103] O. Povstyan,et al. Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370 , 2014, British journal of pharmacology.
[104] Daniel L. Minor,et al. Structural Insight into KCNQ (Kv7) Channel Assembly and Channelopathy , 2007, Neuron.
[105] Nicole Schmitt,et al. The Acrylamide (S)-2 As a Positive and Negative Modulator of Kv7 Channels Expressed in Xenopus laevis Oocytes , 2009, PloS one.
[106] Prem Puri,et al. Decreased expression of Kv7 channels in Hirchsprung's disease. , 2017, Journal of pediatric surgery.
[107] Li Li,et al. Selective targeting of M‐type potassium Kv7.4 channels demonstrates their key role in the regulation of dopaminergic neuronal excitability and depression‐like behaviour , 2017, British journal of pharmacology.
[108] A. Amoresano,et al. Subtype-Selective Activation of Kv7 Channels by AaTXKβ(2–64), a Novel Toxin Variant from the Androctonus australis Scorpion Venom , 2013, Molecular Pharmacology.
[109] Geoffrey W. Abbott,et al. Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket , 2018, Nature Communications.
[110] Zhuxi Chen,et al. The gating charge pathway of an epilepsy-associated potassium channel accommodates chemical ligands , 2013, Cell Research.
[111] Alice W Wang,et al. Sequence determinants of subtype‐specific actions of KCNQ channel openers , 2017, The Journal of physiology.
[112] D. A. Brown,et al. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone , 1980, Nature.
[113] J. Devaux,et al. Calmodulin orchestrates the heteromeric assembly and the trafficking of KCNQ2/3 (Kv7.2/3) channels in neurons , 2014, Molecular and Cellular Neuroscience.
[114] Mark J. Suto,et al. N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. , 2011, ACS medicinal chemistry letters.
[115] W. A. Wilson,et al. N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A Novel, Selective KCNQ2/Q3 Potassium Channel Activator , 2008, Molecular Pharmacology.
[116] Yasunori Sato,et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[117] F Zhang,et al. Modulation of Kv7 potassium channels by a novel opener pyrazolo[1,5‐a]pyrimidin‐7(4H)‐one compound QO‐58 , 2013, British journal of pharmacology.
[118] Nicole Schmitt,et al. Differential Effects of ICA-27243 on Cloned KV7 Channels , 2010, Pharmacology.
[119] A. Brooks-Kayal,et al. A KCNQ channel opener for experimental neonatal seizures and status epilepticus , 2009, Annals of neurology.
[120] Qi Gao,et al. (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons. , 2004, Bioorganic & medicinal chemistry letters.
[121] Dominik Irnich,et al. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial , 2012, Journal of Translational Medicine.
[122] G. Seebohm,et al. Atomic basis for therapeutic activation of neuronal potassium channels , 2015, Nature Communications.
[123] Lezanne Ooi,et al. Transcriptional repression of the M channel subunit Kv7.2 in chronic nerve injury , 2011, PAIN®.
[124] Fan Zhang,et al. European Journal of Medicinal Chemistry , 2022 .
[125] X Zhou,et al. Novel role of KCNQ2/3 channels in regulating neuronal cell viability , 2011, Cell Death and Differentiation.
[126] Guenter W Gross,et al. Pharmacodynamics of potassium channel openers in cultured neuronal networks. , 2014, European journal of pharmacology.
[127] Nicole Schmitt,et al. From Pan-Reactive KV7 Channel Opener to Subtype Selective Opener/Inhibitor by Addition of a Methyl Group , 2014, PloS one.
[128] Andrew M. White,et al. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy , 2017, Neuropharmacology.
[129] Manoj Kumar,et al. Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators , 2016, Molecular Pharmacology.
[130] J. Mikkelsen,et al. Retigabine: chemical synthesis to clinical application. , 2006, CNS drug reviews.
[131] A. Gurney,et al. Functional expression of KCNQ (Kv7) channels in guinea pig bladder smooth muscle and their contribution to spontaneous activity , 2013, British journal of pharmacology.
[132] Winfried Schlee,et al. Potassium channels as promising new targets for pharmacologic treatment of tinnitus: Can Internet-based ‘crowd sensing’ initiated by patients speed up the transition from bench to bedside? , 2016, Expert opinion on therapeutic targets.
[133] Thomas Friedrich,et al. A carboxy‐terminal domain determines the subunit specificity of KCNQ K+ channel assembly , 2003, EMBO reports.
[134] Nir Ben-Tal,et al. Targeting the voltage sensor of Kv7.2 voltage-gated K+ channels with a new gating-modifier , 2010, Proceedings of the National Academy of Sciences.
[135] L. Cribbs,et al. Differential Activation of Vascular Smooth Muscle Kv7.4, Kv7.5, and Kv7.4/7.5 Channels by ML213 and ICA-069673 , 2014, Molecular Pharmacology.
[136] Haibo Yu,et al. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. , 2011, ACS chemical neuroscience.
[137] Robert Hermann,et al. N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. , 2006, Metabolism: clinical and experimental.
[138] B. Attali,et al. A Tale of Switched Functions: From Cyclooxygenase Inhibition to M-Channel Modulation in New Diphenylamine Derivatives , 2007, PloS one.
[139] Mark S. Shapiro,et al. Affinity for phosphatidylinositol 4,5-bisphosphate determines muscarinic agonist sensitivity of Kv7 K+ channels , 2009, The Journal of general physiology.
[140] Sowmya Chinnaiyan,et al. A comparative study of efficacy and safety of flupirtine versus piroxicam in postoperative pain in patients undergoing lower limb surgery , 2017, Journal of pain research.
[141] Karen Methling,et al. Investigation of the in Vitro Metabolism of the Analgesic Flupirtine , 2009, Drug Metabolism and Disposition.
[142] Min Li,et al. Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers , 2008, Proceedings of the National Academy of Sciences.
[143] Yang Li,et al. Regulation of Kv7 (KCNQ) K+ Channel Open Probability by Phosphatidylinositol 4,5-Bisphosphate , 2005, The Journal of Neuroscience.
[144] Edeltraut Garbe,et al. Erratum to: Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database , 2015, European Journal of Clinical Pharmacology.
[145] Holger Lerche,et al. The New Anticonvulsant Retigabine Favors Voltage-Dependent Opening of the Kv7.2 (KCNQ2) Channel by Binding to Its Activation Gate , 2005, Molecular Pharmacology.
[146] Laura Micheli,et al. Effects of natural and synthetic isothiocyanate-based H2S-releasers against chemotherapy-induced neuropathic pain: Role of Kv7 potassium channels , 2017, Neuropharmacology.
[147] Andrew M. White,et al. Flupirtine effectively prevents development of acute neonatal seizures in an animal model of global hypoxia , 2015, Neuroscience Letters.